Globally the healthcare model is being transformed. The economic and regulatory landscape coupled with fundamental changes in drug product development mean more change for the pharma and life sciences industry than ever before.
Pharma and life sciences mergers, takeovers and inversions dominate business headlines. Achieving the promised synergies whether research, operational or financial, requires detailed upfront consideration coupled with well thought through post deal execution. Talk to us first - to structure successfully and drive value from these transactions requires upfront consideration.
Cost pressures from reimbursers together with the need to prove the efficacy of products has led to shifting values in the supply chain. Ireland’s location, long established industry involvement and our low tax rates mean Ireland is an ideal centre to locate these activities.
Continued focus on reimbursement of intangible assets (patents etc.) means that the link between profits and substance is more critical than ever. With more than 370 pharma and life sciences companies located in Ireland, there is significant opportunity to bolt-on value added activities to existing operations, bolstering your substance in a robust, tax efficient manner.
Regulatory success is vital for all pharma and life sciences companies. Regulatory hurdles are ever increasing and the pressure to meet and exceed compliance standards continues to grow. The need for a lean and highly efficient regulatory compliance framework has never been greater.
We are working actively with our clients on these challenges, helping to design practical and commercial solutions and would love the chance to discuss these with you.